The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.
Antonia M JoussenSebastian WolfPeter K KaiserDavid BoyerThomas SchmelterRupert SandbrinkOliver ZeitzGesa DeegAnnett RichterTorsten ZimmermannJoachim HoechelUlf BuetehornWalter SchmittBrigitte StemperMichael K BoettgerPublished in: British journal of clinical pharmacology (2018)
The programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaborate post hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye).